Founding scientists of SEAL Therapeutics (Prof. Markus A. Rüegg and Dr. Judith Reinhard) have a long-standing collaboration with Prof. Peter Yurchenco and colleagues at Rutgers, the State University of New Jersey (USA), who contributed to SEAL technology development. SEAL Therapeutics has an exclusive license to the patented technology from the University of Basel and Rutgers and is actively collaborating with Rutgers' scientists.

SEAL Therapeutics scientists have excellent contacts to key opinion leaders and clinicians in Switzerland, Europe and the US who have strong interest in finding a treatment for LAMA2 MD patients.

Support by the Swiss Foundation for Research on Muscle Diseases
SEAL Therapeutics and the Swiss Foundation for Research on Muscle Diseases (FSRMM) have teamed-up in their desire to make this innovative treatment approach available to LAMA2 MD patients as soon as possible. The foundation has invested in SEAL Therapeutics to support the teams' efforts towards clinical development and registration.

Intended collaboration with Pharma partner
SEAL Therapeutics continues to develop the treatment modalities preclinically and is searching for a qualified pharma partner with experience in advanced gene therapy technologies for clinical development. With the right partner, SEAL Therapeutics ultimately aims to make this innovative treatment approach available to LAMA2 MD patients and their families.